Trans-Atlantic Cooperation

Technology Transfer Office

Director

Johan C. Haveland

Washington DC 03.12.04

University of Bergen

• 7 faculties• +17 000 students• 2 800 faculty and staff

• urban• high quality research• international collaborations

Profile

• research• education• communication

• marine environment• international co-operation

Track Record and projects

• 2 spin-outs sold for $20M+ each

• 2 running spinouts with more than $7M annual revenue

• 18 running spinouts

• New patents

– Methane Hydrate (US based oil company)

– Platform technology for bio-nano (tunnelling nano tubes)

– MR-imaging algorithm for rapid pictures from MRi-scanners

Hans-Herrmann Gerdes et. Al. – TNTs published in Science 13.02.04

Establishing US biotech comp. in Bergen

• Currently developing collaboration model with a San Francisco biotech company– using IPR owned by biotech – using unique UiB expertise

and positioning towards translational medicine

– building Norwegian role in international market

– capitalising on biotech’s existing sales network

• Goal: new joint-owned company in Norway

• Agreed Goal – – Q2 2005: proof of concept; – Q3 2005: start-up.

UniTargetingResearch

• Protein drugs: a $33 bn industry (growth 30%)– Large product pipeline– Considerably undersized production capacity

• UTR® technology: up to 30-fold production yields.– Genetically engineered vectors for mammalian cell production– Boosts secretion of proteins

• Also intracellular & membrane proteins: purify from medium, not cells!

– Customers: biopharma, contract manufacturers, small biotech

• Validated for antibody production and gene therapy.

• Management and advisors from Serono, Eli Lilly, leading academia.

• Raising €1-3 mln.

Novel Diagnostics• Test kit for early detection of colorectal cancer

– Emerging screening market Europe $6 billion

– Norway: 3000 kits sold

– Rollout plan for Europe

• Acute phase detection of infectious disease

– Significantly improves $1,9 bn ELISA platform

– HIV: ongoing clinical trials South Africa

– Tuberculosis: ongoing clinical trials by bioMerieux.

• Management, executives from Abbott Labs, Johnson & Johnson, Murex Diagnostics, Wellcome Diagnostics (Now GlaxoSmithKline)

• Raising €3-10 mln, €3 placed

NAT

Am

ou

nt

HIV infected

20

EIA

10

PlasmAcute®

MediMush• Biopharmaceuticals and nutraceuticals from

medicinal mushrooms, high end market: $2-3 bn

• MediMush production (patented)– Ingredients of superior quality, purity, and at a

fraction of current costs• Key issues to supplement, nutraceuticals

suppliers• Enables oral medicine delivery,

Sine Parmaceautical Company (China)

• #1 Product (Lentinan), under validation by General Nutrition Company (USA)– Animal testing with US National Cancer Institute

and University of Louisiana.• Management from nutraceuticals business,

academia.• Raising €1-3 million

Lentinan for injection

Shitake

Sarsia Innovation Seed Capital

Meltzer Foundation

Unifob Foundation

Phases of commercialisation

IdeasProject

Develop.Seed

CapitalSales/IPO

Regional TTO

Inc from 22.12.04

Service providers/

researchers

UiB, University Hospital, Institte of Marine Research,Bergen University College, CMR, NIFES

ForInnva

InnoVest

Incubator

Start Up Investment in growth

Venture Capital

Services Material Transfer AgreementIndustrial cooperationIPR Management (external financing)Idea - advising

Commercialisation - ResourcesProject evaluation/Market identificationScientific and Market VerificationUnique technology (patent search and filing)Licensing vs start-up models…Proof of Concept: Prototype Preseed fundingSelection of ideas for commercialization

Main Challenges for Regional TTO

IdeasProject

Develop.Seed

Capital

Venture Capital

Sales/IPO

Pre-Seed funding

Seed Capital

Venture-kapital

Early selection citerias

Market Evaluation

Fewer companies

Companies ready for

VC

Develop internal

skills

Attract capital

Trans-Atlantic Help

• TTO - Network for early stage selection of ideas

• Understanding of VC

• US Network for licencing